Phase 3 Psoriasis Trial, Recruiting NCT06937060 Sponsor: The University of Hong Kong Condition: Psoriasis
Back to Psoriasis

Phase 3 Psoriasis Trial, Recruiting

NCT06937060
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with psoriatic disease (a skin and/or joint condition related to psoriasis) for at least 6 months before signing the consent form
  • You are between 18 and 75 years old
  • You are of Chinese ethnicity
  • You have moderate to severe psoriasis, based on a standard skin assessment score
  • You are overweight (BMI 27 or above) with at least one related health condition such as high blood pressure, type 2 diabetes, or high cholesterol — OR you are obese (BMI 30 or above)
  • You are currently on a stable dose of your usual psoriasis treatment
  • You are able and willing to follow the study requirements
  • If you are a woman who is sexually active and not yet through menopause, you agree to either abstain from sex or use 2 effective forms of contraception

Who may not be able to join:

  • You are unwilling to give your consent to participate
  • You have a medical reason why you cannot take a type of medication called a GLP-1 receptor agonist (confirm with trial site)
  • You have a history of pancreatitis (inflammation of the pancreas)
  • You have a personal or family history of a certain type of thyroid cancer (MTC) or a condition called MEN (confirm with trial site)
  • You have a known allergy to semaglutide or any of its ingredients
  • You have Type 1 diabetes
  • You have gallbladder disease
  • You currently have cancer, or have had cancer within the past 5 years
  • You have an active infection that has required antibiotic, antiviral, or antifungal treatment within the past 4 weeks
  • You are pregnant or breastfeeding — you should let your healthcare provider know if you think you may be pregnant
  • You have previously had an allergic reaction to the study medication
  • You have a serious psychiatric (mental health) illness
  • You have received a live or weakened vaccine in the last 28 days before joining the study
  • You have had issues with alcohol or substance misuse in the past 6 months
  • You have a history of suicide attempts or are currently having thoughts of suicide

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Man Ho Martin Chung, The University of Hong Kong

Phone: 22553111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
20 March 2025
Est. completion
31 July 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

Change in mean Psoriasis Area and Severity Index (PASI) before and after semaglutide treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov